Paradoxical decrease in high density lipoprotein-cholesterol associated with statin and fenofibrate combination therapy

Abstract

Get full access to this article

View all access options for this article.

References

Sviridov D. , Nestel P. Genetic factors affecting HDL levels, structure, metabolism and function . Curr Opin Lipidol 2007;18:157-63.

Lan D. , Silver D. Fenofibrate induces a novel degradation pathway for scavenger receptor B-I independent of PDZK1. J Biol Chem 2005 ;280:23390-6.

Nissen S. , Nicholls S. , Wolski K. et al. Effect of a potent and selective PPAR·agonist in patients with atherogenic dyslipidaemia or hypercholesterolaemia. Two randomised controlled trials. JAMA 2007;297:1362-73.

Hiukka A. , Leinonen E. , Jauhainen M. et al. Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus. Diabetologia 2007;EPub ahead of print

Ribas V. , Palomer X. , Roglans N. et al. Paradoxical exacerbation of combined hyperlipidaemia in human apolipoprotein A-II transgenic mice treated with fenofibrate. Biochimica et Biophysica Acta 2005;1737:130-7

Gilde A. , Fruchart JC , Staels B. Peroxisome proliferator-activated receptors at the crossroads of obesity, diabetes, and cardiovascular disease. JACC 2006;48(suppl):A24-A32.

Tai E.M. , Collins D. , Robins S. et al. The L162V polymorphism at the peroxisome proliferator activated receptor alpha locus modulates the risk of cardiovascular events associated with insulin resistance and diabetes mellitus: The Veterans Affairs HDL Intervention Trials (VA-HIT). Atherosclerosis 2006;187:153-60.

Olukoga A. Paradoxical severe decrease in serum HDL-cholesterol after treatment with a fibrate. J Clin Pathol 2002;55:718.

Gutschi L. , Malcolm J. , Favreau C. , Ooi T. Paradoxically decreased HDL-cholesterol levels associated with rosiglitazone therapy. Ann Pharmacother 2006;40:1672-6.

10.

Collinson PO , Hjelm CJ , Canep-Anson R. Paradoxical high-density lipoprotein reduction induced by fenofibrate and ciprofibrate. Ann Clin Biochem 1996;33:159-61.

11.

Oleesky D. , Mir M. Paradoxical high-density lipoprotein reduction induced by fibrate therapy . Ann Clin Biochem 1997:34:573-4.

12.

Chandler HA , Batchelor AJ Ciprofibate and lipid profile. Lancet 1994;344:128-9.

13.

McLeod AJ , Warren RJ , Armitage M. Ciprofibrate and lipid profile. Lancet 1994;344;955.

14.

Capps NE Lipid profiles on fibric-acid derivatives. Lancet 1994;344;684-5.

15.

Shetty C. , Balasubramani M. , Capps N. et al. Paradoxical HDL-C reduction during rosiglitazone and fibrate treatment. Diabet med 2007;24:94-7.

16.

Murali M. , Kratz A. , Finberg K. Case 40-2006: A 64 year old man with anaemia and a low level of HDL-cholesterol . N Engl J Med 2006;355:2772-9.

17.

Normen L. , Frohlich J. , Montaner J. et al. Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL cholesterol. Diabetes Care 2004;27:2241-2.

18.

McLeod AJ , Warren RJ , Armitage M. Abnormal lipid profiles on fibrate derivatives . Lancet 1996;347:261.

19.

Crook M.A. , Lynas J. , Wray R. A paradoxical severe decrease in serum HDL-cholesterol after treatment with a fibrate. J Clin Pathol 2000;53:796-7.

20.

Seber S. , Ucak S. , Basat O. , Altuntas Y. The effect of dual PPAR-α/γ stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients . Diabetes Res Clin Pract 2006;71:52-8.